European Union drugs agency endorses Gilead's remdesivir as COVID-19 treatment

  • European Union drugs agency endorses Gilead's remdesivir as COVID-19 treatment

European Union drugs agency endorses Gilead's remdesivir as COVID-19 treatment

Hetero stated that Covifor (Remdesivir) will be provided in a 100 mg vial (injectable) and must be administered intravenously in a hospital or intensive care unit under the supervision of a healthcare practitioner.

The chairman of the Hetero Group also stated that "with the rising number of COVID-19 cases in the nation, the endorsement for the supply of Covifor (Remdesivir) drug can prove to be a game-changer because clinical results are positive and satisfactory". Along with Delhi and Maharashtra, Gujarat, Tamil Nadu and Telangana will receive the first batch of the drug that has been named COVIFOR. Six doses of the drug will be provided in the aforementioned timeframe.

AFP reports that at least two major U.S. studies have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients.

The company said that the drug will be available only through hospitals and government and not through retail.

Odisha may get its first consignment of remdesivir (brand name Covifor) and favipiravir (brand name FabiFlu), the two drugs approved for Covid-19 treatment in India, within the next four days. The cost of the product is Rs 5,400 per bottle. The next batch of the drug is to be shipped to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Kochi, Trivandrum and Goa.

The European Medicines Agency (EMA) stated that the anti-inflammatory drug ought to be authorized to be used to treat individuals with all the coronavirus. It started the rolling review of remdesivir in April, well before Gilead formally filed for approval of the drug on 5 June. Remdesivir is an injective vial, manufactured by Hyderabad-based pharma company Hetero, and is recommended for critical patients.

Along with Hetero, three Indian companies, including Cipla, Jubilant, and the domestic arm of Mylan, have signed non-exclusive voluntary licencing agreements with Gilead Sciences.

European Medicines Agency (EMA) recommended on Thursday granting a conditional marketing authorization (CMA) to Gilead's antiviral drug called remdesivir, for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen.

A prior study in the US, headed by the National Institutes of Health recently discovered it provokes an average recovery period from 15 days to 11 times in hospitalized patients with acute illness.